MabVax Therapeutics Holdings to Present at the 2015 LD Micro Invitational Investor Conference on June 2nd at 4:30 PM EDT

May 28, 2015, 08:00 ET from MabVax Therapeutics Holdings, Inc.

SAN DIEGO, May 28, 2015 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company, announced today that its President and Chief Executive Officer, David Hansen, will present at the LD Micro Invitational Investor Conference being held at the Luxe Sunset Hotel in Bel Air, California on June 1-3, 2015.

Mr. Hansen will present a corporate update including highlights from the significant progress made in the last year and plans for continuing development of its lead antibody candidate HuMab 5B1 as a diagnostic product and therapeutic agent in the diagnosis and treatment of GI cancers and specifically pancreatic cancer. The antibody product is scheduled to enter Phase I clinical trials later this year. Mr. Hansen will also update investors and interested corporate entities on the therapeutic cancer vaccine program, which has two products in late stage Phase II clinical trials. He will discuss the upcoming Phase II trial in the childhood cancer neuroblastoma for which MabVax's therapeutic vaccine candidate received an Orphan Drug Designation from FDA in September 2014.

Mr. Hansen will present on Tuesday, June 2nd at 4:30 pm EDT / 1:30 pm PDT. The presentation will be webcast live and available for replay at http://wsw.com/webcast/ldmicro8/mbvx. The replay will be available for 90 days following the live broadcast at http://wsw.com/webcast/ldmicro8/mbvx as well as on the investor relations section of the MabVax website at http://www.mabvax.com.

In addition, Mr. Hansen will be having one-on-one meetings with institutional investors throughout the event. If you would like to schedule a one-on-one meeting, please contact LD Micro at 408-457-1042 or Robert Prag, President of The Del Mar Consulting Group, Inc. at (858) 794-9500.

About LD Micro:

LD Micro is an investment newsletter firm that focuses on finding undervalued companies in the micro-cap space. Since 2002, the firm has published reports on select companies throughout the year. The firm also hosts the LD Micro Main Event in December. It is a non-registered investment advisor. For more information, please contact 408-457-1042 or visit www.ldmicro.com.

About MabVax:

MabVax Therapeutics Holdings, Inc. is a clinical stage oncology drug development company focused on the development of human antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax is preparing to enter two Phase 1 clinical trials of HuMab 5B1 – one for the diagnosis, and the other for the treatment, of metastatic pancreatic cancer in late 2015. MabVax has the exclusive license to therapeutic vaccines from Memorial Sloan Kettering Cancer Center. MabVax has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof of concept Phase II multi-center clinical trials, and a vaccine targeting neuroblastoma that will be ready for Phase II clinical trial later this year. Additional information about the Company is available at www.mabvax.com.

Forward Looking Statements:
This press release that provides a corporate update and financial results for the three months ended March 31, 2015, contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the Company's development pipeline and status of financial resources subsequent to the end of the quarter. We have no assurance that all of the product development pipeline will be fully developed by the Company. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in the Company's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2014, as amended and supplemented from time to time and the Company's Quarterly Reports on Form 10-Q and other filings submitted by the Company to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The parties do not undertake any obligation to update forward-looking statements contained in this press release.

Investor Contact:

Robert B. Prag, President
The Del Mar Consulting Group, Inc.
858-794-9500
bprag@delmarconsulting.com

or

Scott Wilfong, President
Alex Partners, LLC
425-242-0891
scott@alexpartnersllc.com

SOURCE MabVax Therapeutics Holdings, Inc.



RELATED LINKS

http://www.mabvax.com